Brand Name | Status | Last Update |
---|---|---|
aminosyn ii | New Drug Application | 2022-05-04 |
aminosyn-pf | New Drug Application | 2022-07-21 |
clinimix | New Drug Application | 2021-04-13 |
clinimix e | New Drug Application | 2021-04-13 |
clinisol | ANDA | 2018-06-01 |
enbrace hr | unapproved drug other | 2025-01-02 |
enlyte | unapproved drug other | 2022-07-01 |
kabiven | New Drug Application | 2023-08-02 |
paxlyte | unapproved drug other | 2024-12-19 |
perikabiven | New Drug Application | 2023-08-07 |
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
---|---|---|---|---|---|---|---|---|---|
Atrial fibrillation | D001281 | EFO_0000275 | I48.0 | 4 | 33 | 41 | 74 | 131 | 279 |
Thrombosis | D013927 | — | — | 24 | 37 | 78 | 45 | 54 | 228 |
Thromboembolism | D013923 | — | — | 17 | 44 | 74 | 34 | 54 | 216 |
Venous thromboembolism | D054556 | EFO_0004286 | I74 | 13 | 37 | 61 | 24 | 50 | 179 |
Healthy volunteers/patients | — | — | — | 128 | 5 | — | 1 | 5 | 139 |
Venous thrombosis | D020246 | — | I82.40 | 11 | 20 | 57 | 19 | 34 | 134 |
Embolism | D004617 | — | — | 8 | 9 | 30 | 17 | 30 | 90 |
Stroke | D020521 | EFO_0000712 | I63.9 | 3 | 20 | 25 | 22 | 24 | 86 |
Hypercholesterolemia | D006937 | — | — | 10 | 15 | 42 | 12 | 7 | 84 |
Covid-19 | D000086382 | — | U07.1 | 9 | 40 | 26 | 8 | 11 | 83 |
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
---|---|---|---|---|---|---|---|---|---|
Schizophrenia | D012559 | EFO_0000692 | F20 | 3 | 12 | 2 | — | 3 | 17 |
Hereditary angioedemas | D054179 | EFO_0004131 | — | 4 | 3 | 5 | — | 1 | 12 |
Angioedema | D000799 | EFO_0005532 | T78.3 | 4 | 3 | 5 | — | 1 | 12 |
Non-small-cell lung carcinoma | D002289 | — | — | 7 | 6 | 1 | — | — | 11 |
Psychotic disorders | D011618 | — | F20.81 | 2 | 6 | 2 | — | 3 | 11 |
Intracranial thrombosis | D020767 | — | — | 1 | 2 | 5 | — | 2 | 9 |
Pneumonia | D011014 | EFO_0003106 | J18 | — | 6 | 3 | — | — | 8 |
Hiv infections | D015658 | EFO_0000764 | B20 | 1 | 4 | 4 | — | 1 | 8 |
Cerebral hemorrhage | D002543 | — | — | — | 2 | 4 | — | 1 | 7 |
Embolic stroke | D000083262 | — | — | — | 1 | 5 | — | 2 | 7 |
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
---|---|---|---|---|---|---|---|---|---|
Breast neoplasms | D001943 | EFO_0003869 | C50 | 3 | 3 | — | — | 3 | 9 |
Lung neoplasms | D008175 | — | C34.90 | 3 | 4 | — | — | 1 | 7 |
Nephrotic syndrome | D009404 | EFO_0004255 | N04 | 3 | 2 | — | — | 1 | 5 |
Nephrosis | D009401 | — | — | 3 | 2 | — | — | 1 | 5 |
Non-alcoholic fatty liver disease | D065626 | EFO_0003095 | K75.81 | 2 | 2 | — | — | 2 | 5 |
Fatty liver | D005234 | EFO_0003934 | — | 2 | 2 | — | — | 2 | 5 |
Ovarian neoplasms | D010051 | EFO_0003893 | C56 | 2 | 3 | — | — | 1 | 5 |
Hepatitis | D006505 | — | K75.9 | 2 | 3 | — | — | 1 | 4 |
Glioma | D005910 | EFO_0000520 | — | 2 | 1 | — | — | 1 | 4 |
Myeloproliferative disorders | D009196 | — | D47.1 | 1 | 1 | — | — | 1 | 3 |
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
---|---|---|---|---|---|---|---|---|---|
Drug interactions | D004347 | — | — | 5 | — | — | — | — | 5 |
Therapeutic equivalency | D013810 | — | — | 5 | — | — | — | — | 5 |
Morbid obesity | D009767 | EFO_0001074 | — | 2 | — | — | — | 2 | 4 |
Coagulation protein disorders | D020147 | — | — | 3 | — | — | — | 1 | 4 |
Insulin resistance | D007333 | EFO_0002614 | E88.819 | 2 | — | — | — | 2 | 4 |
Hepatic insufficiency | D048550 | — | — | 3 | — | — | — | 1 | 4 |
Crohn disease | D003424 | EFO_0000384 | K50 | 1 | — | — | — | 1 | 2 |
Proteinuria | D011507 | — | R80 | 1 | — | — | — | 1 | 2 |
Pharmacological phenomena | D000069437 | — | — | 2 | — | — | — | — | 2 |
Pituitary acth hypersecretion | D047748 | EFO_1001110 | E24.0 | 1 | — | — | — | 1 | 2 |
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
---|---|---|---|---|---|---|---|---|---|
Aortic dissection | D000784 | — | I71.0 | — | — | — | — | 6 | 6 |
Frailty | D000073496 | — | R53.1 | — | — | — | — | 3 | 3 |
Brain diseases | D001927 | — | G93.40 | — | — | — | — | 3 | 3 |
Irritable bowel syndrome | D043183 | EFO_0000555 | K58 | — | — | — | — | 3 | 3 |
Postmenopause | D017698 | — | — | — | — | — | — | 2 | 2 |
Disease progression | D018450 | — | — | — | — | — | — | 2 | 2 |
Ataxia | D001259 | — | R27.0 | — | — | — | — | 2 | 2 |
Mutagenesis | D016296 | — | — | — | — | — | — | 2 | 2 |
Hypersensitivity | D006967 | EFO_0003785 | T78.40 | — | — | — | — | 2 | 2 |
Nutritional requirements | D009751 | — | — | — | — | — | — | 2 | 2 |
Drug common name | Serine |
INN | dexfosfoserine |
Description | L-serine is the L-enantiomer of serine. It has a role as a human metabolite, an algal metabolite, a Saccharomyces cerevisiae metabolite, an Escherichia coli metabolite and a mouse metabolite. It is a serine family amino acid, a proteinogenic amino acid, a L-alpha-amino acid and a serine. It is a conjugate base of a L-serinium. It is a conjugate acid of a L-serinate. It is an enantiomer of a D-serine. It is a tautomer of a L-serine zwitterion. |
Classification | Small molecule |
Drug class | — |
Image (chem structure or protein) | ![]() |
Structure (InChI/SMILES or Protein Sequence) | N[C@@H](CO)C(=O)O |
PDB | — |
CAS-ID | 56-45-1 |
RxCUI | — |
ChEMBL ID | CHEMBL11298 |
ChEBI ID | 17115 |
PubChem CID | 5951 |
DrugBank | DB00133 |
UNII ID | VI4F0K069V (ChemIDplus, GSRS) |